NewsBenzingaImmuneering社、atebimetinibのデータにより、RAS変異大腸がんおよび肺がんモデルにおけるPD-1チェックポイント阻害の活性向上を示し、大腸がんモデルで50%の持続的完全退縮を実証と発表 Immuneering社、atebimetinibのデータにより、RAS変異大腸がんおよび肺がんモデルにおけるPD-1チェックポイント阻害の活性向上を示し、大腸がんモデルで50%の持続的完全退縮を実証と発表 Benzinga 2026.11.06 14:02 (GMT+0) Open on Benzinga Other news Jensen Huang Offers Nvidia Return If Board Wants Him Back Nvidia Tracks Seventh Weekly Loss Ahead of Earnings ‘You Don’t Want Rogue Agents’: Jamie Dimon Shuts Meta’s Muse AI Agent Out of JPMorgan. What It Means for META Stock. Investors Press for Answers From Nvidia, Where ‘Everything Has Changed’ Jensen Huang Signals Return to Nvidia CEO Role: Says Outpouring of Outside Support Is 'Stunning' Do Wall Street Analysts Like Diamondback Energy Stock?
‘You Don’t Want Rogue Agents’: Jamie Dimon Shuts Meta’s Muse AI Agent Out of JPMorgan. What It Means for META Stock.